First Time Loading...

Prescient Therapeutics Ltd
ASX:PTX

Watchlist Manager
Prescient Therapeutics Ltd Logo
Prescient Therapeutics Ltd
ASX:PTX
Watchlist
Price: 0.048 AUD -4% Market Closed
Updated: May 3, 2024

Prescient Therapeutics Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prescient Therapeutics Ltd
Operating Income Peer Comparison

Comparables:
IMM
MSB
CSL
CUV
TLX

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Prescient Therapeutics Ltd
ASX:PTX
Operating Income
-AU$7.7m
CAGR 3-Years
-30%
CAGR 5-Years
-21%
CAGR 10-Years
-21%
Immutep Ltd
ASX:IMM
Operating Income
-AU$46.9m
CAGR 3-Years
-29%
CAGR 5-Years
-24%
CAGR 10-Years
-13%
Mesoblast Ltd
ASX:MSB
Operating Income
-$55.3m
CAGR 3-Years
21%
CAGR 5-Years
9%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Operating Income
$3.7B
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Operating Income
AU$50.8m
CAGR 3-Years
36%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Operating Income
AU$17.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Prescient Therapeutics Ltd's Operating Income?
Operating Income
-7.7m AUD

Based on the financial report for Dec 31, 2023, Prescient Therapeutics Ltd's Operating Income amounts to -7.7m AUD.

What is Prescient Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-21%

Over the last year, the Operating Income growth was -61%. The average annual Operating Income growth rates for Prescient Therapeutics Ltd have been -30% over the past three years , -21% over the past five years , and -21% over the past ten years .